ZyVersa Therapeutics, Inc.

NasdaqCM ZVSA

ZyVersa Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 122.92 M

ZyVersa Therapeutics, Inc. Cash and Short-Term Investments is USD 122.92 M for the quarter ending September 30, 2024, a 7,686.11% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

ZyVersa Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 1.58 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: ZVSA

ZyVersa Therapeutics, Inc.

CEO	Mr. Stephen C. Glover
IPO Date	Feb. 11, 2022
Location	United States
Headquarters	2200 N. Commerce Parkway
Employees	7
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Key trends

Past 5 years